Vitamin K2 sensitizes the efficacy of venetoclax in acute myeloid leukemia by targeting the NOXA-MCL-1 pathway
Fig 5
Gene expressions of BCL-2 family members after treatment with VK2 and/or VEN in HL-60 and SKM-1 cells.
(A, B) HL-60 and SKM-1 cells were treated with VK2 (10 μM for HL-60, 25 μM for SKM-1) and/or VEN (25 nM for HL-60, 2.5 μM for SKM-1) for 24 h and 48 h. Gene expressions of the BCL-2 family members were assessed by real-time PCR. Data are presented as the mean ± SD. *p<0.05 vs. cont. n = 3. (C, D) Effect of NAC treatment on NOXA mRNA expression was assessed by real-time PCR with HL-60 and SKM-1 cells. Data are presented as the mean ± SD., *p<0.05 vs. cont, #p<0.05 v.s. NAC (-), n = 3.